Showa Inan General Hospital
Komagane, Nagano, 399-4117, Japan
Location status: Recruiting
Location contact
Yamaguchi Yukari
CONTACT
Recruiting
NCT Number: NCT04535882
Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD
We attempt to examine the association between serum leucine-rich alpha-2 glycoprotein (LRG) levels and endoscopic activity in patients with possible ulcerative colitis (UC) or Crohn's disease (CD) to determine whether LRG was a predicting marker for UC or CD.
Recruiting
Interested in participating?
Request InfoKey information
About this study
Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy with histology were performed within 7 days.The disease activity of UC and CD patients was evaluated by the Mayo score and Crohn disease activity index (CDAI), respectively. The Mayo endoscopy score was evaluated. UC patients whose Mayo endoscopy score was 2 or 3 were divided into the active UC group.
CD patients whose CDAI >150 were divided into the active CD group.
Who can participate
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients whom possible UC or Crohn disease was suspected
Exclusion criteria
- other autoimmune diseases
- acute or chronic renal failure
- chronic heart diseases
- liver cirrhosis
- cancer
- acute or chronic infections
- ischemic colitis
- infectious colitis
Treatment and study plan
serum leucine-rich alpha-2 glycoprotein (LRG) levels
Diagnostic TestPatients who were diagnosed with possible UC or Crohn disease according to endoscopic, radiological, histological, and clinical criteria were enrolled. Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy were performed within 7 days.
Primary outcomes
-
Serum LRG measurement
Time frame: one year
Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients.
Study contacts
Contact information is provided by the study sponsor or research team.
Sponsors and collaborators
Lead sponsor
Showa Inan General Hospital
Other
Registry information
Official study title
Association Between Serum Leucine-rich Alpha-2 Glycoprotein Levels and Endoscopic Activity of Possible Ulcerative Colitis or Crohn's Disease Colitis
Important dates
- Study start
- 2020
- Primary completion
- 2026
- Study completion
- 2026
- First posted
- Sep 2, 2020
- Registry last updated
- May 13, 2026
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.